GAS5 and metabolic dysfunction-associated steatotic liver disease: Their results suggest that GAS5 is a potent regulator of the miR-29a-3p/NOTCH2 axis while actively involved in NAFLD progression, which recommends it as a potential therapeutic target against NAFLD [125].